Stoke Therapeutics (STOK) Enterprise Value (2019 - 2026)

Stoke Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$343.5 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 3.86% year-over-year to -$343.5 million; the TTM figure through Mar 2026 stood at -$343.5 million (up 3.86% YoY), while the FY2025 annual figure was -$284.7 million, down 31.25% from the prior year.
• Enterprise Value for Q1 2026 stood at -$343.5 million, down from -$284.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$150.1 million in Q3 2024, with the low at -$357.3 million in Q1 2025.
• The 5-year median for Enterprise Value is -$247.7 million (2025), against an average of -$245.4 million.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 30.1% in 2024, then plunged 100.09% in 2025.
• Stoke Therapeutics' Enterprise Value stood at -$229.6 million in 2022, then rose by 12.28% to -$201.4 million in 2023, then fell by 7.7% to -$216.9 million in 2024, then plunged by 31.25% to -$284.7 million in 2025, then decreased by 20.68% to -$343.5 million in 2026.
• Business Quant data shows STOK's Enterprise Value at -$343.5 million in Q1 2026, -$284.7 million in Q4 2025, and -$248.3 million in Q3 2025.